The Expanding Therapeutic Landscape in IgA Nephropathy: Translating New Clinical Evidence and Updated Guidelines Into Managed Care Strategies

Program Description

IgA nephropathy (IgAN) is a progressive disease that can lead to significant kidney damage. With new therapies now available and more on the horizon, staying current on the latest clinical guidance is essential for managed care professionals and pharmacists. This webinar addresses the rapidly changing treatment landscape for IgAN and its impact on patient care and managed care decision-making. Specifically, the focus of this webinar will be on the most updated guideline recommendations for IgAN management, as well as how they inform formulary decision making. Expert faculty will discuss the latest clinical evidence, challenges associated with current treatments, and the overarching goals of therapy. Key discussion points for managed care professionals will include strategies to improve patient access to newer therapies.

Target audience: Managed Care Pharmacist

Type of activity: Application

Release date: October 31, 2025

Expiration date: October 31, 2026

Time to complete activity: 1.0 hours

Learner level: Foundational

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the pathophysiology of IgA nephropathy (IgAN), its clinical and economic burden, and the importance of implementing care pathways that support early diagnosis and intervention
• Analyze updated KDIGO guideline recommendations for IgAN management, including key treatment goals and the disease-specific relevance of proteinuria
• Explore managed care strategies, including considerations for formulary decision making, to ensure patient access to new and emerging IgAN therapies

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-9999-25-353-H01-P. The activity is available for CE credit through October 31, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Darren W. Grabe, PharmD, BS

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP ; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms